• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡瑞利珠单抗诱导的肺腺癌免疫相关中毒性表皮坏死松解症:一例报告及文献综述

Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review.

作者信息

Sun Man, Zhou Huan, Zang Dan, Liu Chen-Guang, Chen Jun

机构信息

Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.

出版信息

Front Oncol. 2025 Jan 13;14:1417936. doi: 10.3389/fonc.2024.1417936. eCollection 2024.

DOI:10.3389/fonc.2024.1417936
PMID:39871939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11769826/
Abstract

Toxic epidermal necrolysis (TEN) is a rare and serious skin reaction. This study reports a case of a patient with lung adenocarcinoma (LUAD) who developed severe TEN after 8 days of treatment with Camrelizumab monotherapy. The patient's condition was effectively relieved with high-dose corticosteroids and intravenous immunoglobulin therapy. The diagnosis and treatment of immune-related TEN are challenging. This is a rare and severe case of TEN associated with the use of Camrelizumab. Additionally, we provide an in-depth understanding of immune-related TEN, summarizing its characteristics and treatment progress through a literature review, aiming to provide reference for the clinical safe application of immune checkpoint inhibitors (ICIs).

摘要

中毒性表皮坏死松解症(TEN)是一种罕见且严重的皮肤反应。本研究报告了一例肺腺癌(LUAD)患者,在接受卡瑞利珠单抗单药治疗8天后发生了严重的TEN。该患者的病情通过大剂量糖皮质激素和静脉注射免疫球蛋白治疗得到有效缓解。免疫相关TEN的诊断和治疗具有挑战性。这是一例与使用卡瑞利珠单抗相关的罕见且严重的TEN病例。此外,我们通过文献综述对免疫相关TEN进行了深入了解,总结了其特征和治疗进展,旨在为免疫检查点抑制剂(ICIs)的临床安全应用提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/87ff64cf4223/fonc-14-1417936-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/8a5316a2cb54/fonc-14-1417936-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/234294203db3/fonc-14-1417936-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/69bdd1b31703/fonc-14-1417936-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/87ff64cf4223/fonc-14-1417936-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/8a5316a2cb54/fonc-14-1417936-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/234294203db3/fonc-14-1417936-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/69bdd1b31703/fonc-14-1417936-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e501/11769826/87ff64cf4223/fonc-14-1417936-g004.jpg

相似文献

1
Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review.卡瑞利珠单抗诱导的肺腺癌免疫相关中毒性表皮坏死松解症:一例报告及文献综述
Front Oncol. 2025 Jan 13;14:1417936. doi: 10.3389/fonc.2024.1417936. eCollection 2024.
2
Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症与免疫检查点抑制剂相关:系统评价。
Front Immunol. 2024 Jul 12;15:1414136. doi: 10.3389/fimmu.2024.1414136. eCollection 2024.
3
Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.PD-1 抑制剂诱导的中毒性表皮坏死松解症后继发苔藓样皮炎:一例病例报告及文献复习。
Immunotherapy. 2023 Oct;15(15):1249-1256. doi: 10.2217/imt-2023-0081. Epub 2023 Aug 10.
4
Case report: Toxic epidermal necrolysis induced by tislelizumab in a patient with esophageal squamous cell carcinoma.病例报告:替雷利珠单抗诱导食管鳞状细胞癌患者发生中毒性表皮坏死松解症。
Front Med (Lausanne). 2024 Dec 23;11:1522525. doi: 10.3389/fmed.2024.1522525. eCollection 2024.
5
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.免疫检查点抑制剂诱导的表皮坏死松解症:评估人口统计学、临床特征和罪魁祸首药物的叙述性综述。
J Dermatol. 2024 Jan;51(1):3-11. doi: 10.1111/1346-8138.17039. Epub 2023 Nov 30.
6
Dermatitis bullosa caused by the immune checkpoint inhibitor camrelizumab: A case report.免疫检查点抑制剂卡瑞利珠单抗引起的大疱性性皮炎:一例报告
World J Clin Cases. 2025 Mar 16;13(8):97677. doi: 10.12998/wjcc.v13.i8.97677.
7
Chemotherapy-induced toxic epidermal necrolysis in a patient with multiple myeloma, a case report and literature review.一名多发性骨髓瘤患者化疗引起的中毒性表皮坏死松解症:病例报告及文献综述
Front Oncol. 2023 Aug 2;13:1227448. doi: 10.3389/fonc.2023.1227448. eCollection 2023.
8
Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report.帕博利珠单抗诱导食管胃交界癌患者发生自身免疫性史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症并伴发肌炎和心肌炎:一例报告
Transl Cancer Res. 2021 Aug;10(8):3870-3876. doi: 10.21037/tcr-21-470.
9
Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.奥希替尼相关中毒性表皮坏死松解症在携带 EGFR 突变的肺癌患者中的应用:病例报告及文献复习。
Medicina (Kaunas). 2020 Aug 11;56(8):403. doi: 10.3390/medicina56080403.
10
Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma.卡瑞利珠单抗联合阿帕替尼治疗晚期胆囊癌后发生的中毒性表皮坏死松解症样反应
Front Oncol. 2021 Oct 29;11:728253. doi: 10.3389/fonc.2021.728253. eCollection 2021.

本文引用的文献

1
Allopurinol: Clinical Considerations in the Development and Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Other Associated Drug Reactions.别嘌醇:史蒂文斯-约翰逊综合征、中毒性表皮坏死松解症及其他相关药物反应的发生发展与治疗中的临床考量
Cureus. 2024 Jul 16;16(7):e64654. doi: 10.7759/cureus.64654. eCollection 2024 Jul.
2
Camrelizumab-induced anaphylactic reaction: a case report and literature review.卡瑞利珠单抗引起的过敏反应:一例病例报告及文献综述
J Chemother. 2025 Jul;37(4):376-382. doi: 10.1080/1120009X.2024.2372525. Epub 2024 Jun 27.
3
Causes and Management of Cutaneous Adverse Drug Reactions: A Comprehensive Review.
皮肤药物不良反应的病因与管理:综述
Cureus. 2024 Mar 1;16(3):e55318. doi: 10.7759/cureus.55318. eCollection 2024 Mar.
4
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.免疫检查点抑制剂诱导的表皮坏死松解症:评估人口统计学、临床特征和罪魁祸首药物的叙述性综述。
J Dermatol. 2024 Jan;51(1):3-11. doi: 10.1111/1346-8138.17039. Epub 2023 Nov 30.
5
Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration.卡瑞利珠单抗致口腔黏膜类天疱疮样反应伴上皮下 CD4+T 细胞浸润
J Oncol Pharm Pract. 2024 Jan;30(1):228-234. doi: 10.1177/10781552231203723. Epub 2023 Oct 11.
6
Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.药物所致严重皮肤不良反应:一项使用美国食品药品监督管理局不良事件报告系统数据库的真实世界药物警戒研究
Front Pharmacol. 2023 Apr 4;14:1117391. doi: 10.3389/fphar.2023.1117391. eCollection 2023.
7
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.免疫检查点抑制剂治疗期间非小细胞肺癌患者外周血中驻留记忆 T 细胞的克隆扩增。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005509.
8
Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).卡瑞利珠单抗治疗不可切除或晚期非小细胞肺癌患者的有效性和安全性:一项多中心真实世界回顾性观察研究(CTONG2004-ADV)
Transl Lung Cancer Res. 2023 Jan 31;12(1):127-140. doi: 10.21037/tlcr-22-852. Epub 2023 Jan 16.
9
[Immune checkpoint inhibitor-induced eosinophilic fasciitis: a case report and literature review].[免疫检查点抑制剂诱导的嗜酸性筋膜炎:一例报告及文献综述]
Zhonghua Nei Ke Za Zhi. 2023 Feb 1;62(2):182-187. doi: 10.3760/cma.j.cn112138-20220403-00245.
10
The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report.抗程序性细胞死亡蛋白-1 治疗对预先存在白癜风的非小细胞肺癌患者色素脱失恶化至恢复的时间窗:1 例病例报告。
Front Immunol. 2022 Aug 16;13:946829. doi: 10.3389/fimmu.2022.946829. eCollection 2022.